Mohammad Kabir
Addiction Medicine · Troy, NYNPI 1326131715
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,050 of the $14,994 with a category attached, or 60.4%. 23 manufacturers reported payments, led by Orexo US, Inc. at 44.7% of the total. Reporting peaked in 2019 at $7,909 and has fallen 69.0% since, to $2,454 in 2025. Among addiction medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $106.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Orexo US, Inc.$7K
- AstraZeneca$2K
- AbbVie$941
- Teva Pharmaceuticals USA, Inc.$622
- Johnson & Johnson$516
- Braeburn Inc.$493
- plus $4K from 17 others
What the payments were for
- Consulting fees$5,00033%
- Travel & lodging$9446%
- Food & beverage$9,05060%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Orexo US, Inc. | 30 | $6,696 |
| AstraZeneca | 15 | $1,742 |
| AbbVie | 8 | $941 |
| Teva Pharmaceuticals USA, Inc. | 8 | $622 |
| Johnson & Johnson(2 entities) | 5 | $516 |
| Braeburn Inc. | 23 | $493 |
| Lilly USA, LLC | 8 | $444 |
| GSK | 4 | $408 |
| Amgen | 3 | $360 |
| Indivior Inc. | 11 | $353 |
| Novo Nordisk | 3 | $346 |
| Vanda Pharmaceuticals Inc. | 3 | $321 |
| Abiomed | 2 | $277 |
| Gilead | 4 | $266 |
| Supernus Pharmaceuticals, Inc. | 3 | $265 |
| Boehringer Ingelheim | 2 | $220 |
| Alkermes, Inc. | 3 | $142 |
| Akebia Therapeutics Inc | 1 | $123 |
| Avanir Pharmaceuticals, Inc. | 1 | $123 |
| Sumitomo Pharma America, Inc. | 1 | $107 |
| Pfizer | 1 | $107 |
| CSL Behring | 1 | $100 |
| Vertex | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,994 in reported general payments places this provider in the 95th percentile of 125 addiction medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 30 | $7,321 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Troy
- Mohammed IsmailTroy$3K
- Edmond HakimiCalverton$125K
- Alain LitwinBronx$124K
- John MarianiNew York$38K
- Stefan KantrowitzNew York$33K
- Alejo ParelladaBrooklyn$22K
- Sean ChappinAlbany$20K
- Sonia LopezJamaica$14K
- Thomas KuettelWorcester$14K
- Ramon RaveloNew York$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.